Atea Pharmaceuticals director proposes 18,252-share sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Atea Pharmaceuticals (AVIR) director Bruce Polsky gave notice of a proposed sale of 18,252 common shares, with an aggregate market value of $72,099.05 and an approximate sale date of November 18, 2026. The notice lists those shares as acquired from the issuer through a stock option exercise paid in cash on November 18, 2026.
Key Figures
Key Terms
Stock Option Exercise financial
Aggregate Market Value financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.